Sun-Novo(SH:688621)2025-02-27 10:25Financial Performance - The company achieved total operating revenue of 1,077.72 million yuan, a year-on-year increase of 15.62%[6] - The net profit attributable to the parent company was 180.29 million yuan, a decrease of 2.42% compared to the previous year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 168.17 million yuan, down 6.61% year-on-year[6] - The earnings per share were 1.61 yuan, a decrease of 2.42% compared to the previous year[4] - The weighted average return on net assets decreased by 1.76 percentage points to 17.46%[4] Assets and Equity - Total assets at the end of the reporting period were 1,985.95 million yuan, an increase of 6.60% from the beginning of the period[6] - Equity attributable to the parent company was 1,103.52 million yuan, up 6.11% from the beginning of the period[6] Business Strategy - The company is focusing on developing innovative drugs with global independent intellectual property rights and increasing R&D investment in cutting-edge fields[7] - The company’s integrated "preclinical + clinical" service model has led to stable growth in market orders despite industry challenges[6] Financial Reporting - The company warns that the financial data presented is preliminary and subject to final audit in the annual report[5]